Division of Biogen Inc.
Latest From Fumapharm AG
We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.
Paying cash up front to scientists, hospitals, biotechs and pharmas in exchange for their royalty stakes in successful drugs has proven profitable for Royalty Pharma. The firm has begun applying its long-term strategy to late-stage clinical candidates in addition to marketed products.
Plus news on recent financings by Vivus, Novira Therapeutics, Theraclone Sciences and Receptos.
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
- Hans Peter Strebel, PhD, Pres. & CEO
- Contact Info
Phone: (41) 41 371 20 46
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.